1835 ET - Hims & Hers Health says it will stop offering compounded semaglutide, a version of the active ingredient in weight-loss drugs Wegovy and Ozempic, after the first quarter. The stoppage comes after the FDA last week determined that shortages of the drugs had been resolved. CEO Andrew Dudum says on a call with analysts that the company will begin notifying customers of the stop in the coming weeks. "I would suspect, you know, just being very direct, that a lot of those patients will try to go into the open market and try to secure a branded option in some form factor," he says, though he adds that the company will continue to offer other forms of weight-loss drugs on its platform. Shares fall 18% in after-hours trading. (connor.hart@wsj.com)
(END) Dow Jones Newswires
February 24, 2025 18:35 ET (23:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.